Marquee Middle Image

Faculty Profile

Barrett Katz, M.D.

Dr. Barrett Katz
 

Professional Interests

Dr. Katz comes to Montefiore and Einstein from both academic medicine and industry, where he has been most recently engaged in the biotech arena and drug development for several years. He served as CEO of Danube Pharmaceuticals and chief medical officer of both Fovea Pharmaceuticals and Eyetech, which brought the first medical therapy for macular degeneration to market. Prior to that, he had a distinguished career in academia, most recently as professor and chairman of the Department of Ophthalmology at the George Washington University School of Medicine. Over the course of his 25-year career, Dr. Katz has earned a reputation as a gifted clinician and teacher as well as an accomplished researcher. He also served as co-director of a joint fellowship in ophthalmologic drug development, regulation and trials co-sponsored by George Washington University and the U.S. Food and Drug Administration.

As a neuro-ophthalmologist, Dr. Katz’s clinical expertise is in treatment of optic nerve diseases, unusual eye movements, and ocular manifestations of systemic diseases. He has joint appointments in the departments of ophthalmology, neurology, and neurosurgery at Montefiore and Einstein.

 Dr. Katz received his medical degree from Case-Western Reserve University School of Medicine. He completed an internship in medicine at Parkland Hospital in Dallas, served as a research staff associate in neuro-virology at the National Institutes of Health, completed a residency in neurology at Harvard University and an ophthalmology residency at Tufts-New England Medical Center. He completed fellowships at Harvard, at the National Hospital for Nervous Disease at Queen’s Square in London, and at the University of California, San Francisco (UCSF). Dr. Katz obtained an M.B.A. in finance and healthcare management from the University of Rochester’s Simon School of Business, and has served on the faculties of the University of California, San Diego, UCSF, and the University of Rochester.

Dr. Katz has authored numerous articles published in peer reviewed journals, and has served on the board of directors for professional societies including the Ophthalmology Research and Education Foundation and the International Eye Foundation. He resides in New York City.

 

Selected Publications

Katz B and Hoyt WF.  Intrapapillary and peripapillary hemorrhage in young patients with incomplete posterior vitreous detachment.  Ophthalmology 102(2):349; 1995.  Katz B.  Infections of the central nervous system.  Walsh and Hoyt’s Clinical Neuro-Ophthalmology, 6th Edition,  Williams & Wilkins, Baltimore, MD., 2004

Katz B and Hoyt WF.  Gaze evoked amaurosis due to vitreopapillary traction,  Am J Ophthalmol.  Apr ;139:631-637,  April 2005.

The Macugen Diabetic Retinopathy Study Group,  Pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema, 
Ophthalmol  113, 1:23-28, 2006.

 

Katz B and Adamis A.  Pegaptinib for Diabetic Macular Edema, in, Retinal Vascular Disease, Joussen AM, Gardner TW, Kirchof B and Ryan SJ, Springer-Verlag, 2007.

 

Starita C, Patel M, Katz B, Adamis AP. Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (macugen) in diabetic retinopathy.  Dev Ophthalmol. 2007;39:122-48..

 

Beck RW, Cleary PA, Trobe JD, et. al.  The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. 
New England Journal of Medicine 329:1764-1769; 1993.

Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial.   Singerman LJ, Masonson H, Patel M, Adamis AP, Buggage R, Cunningham E, Goldbaum M, Katz B, Guyer D. , Br J Ophthalmol. 2008 Dec;92(12):1606-11. 2008.

 

Wrlblewski JJ, Welss JA, Adamis AP, Buggage RR, Cunningham ET, Goldbaum M, Guyer DR, Katz B, Altaweel MM,  Pegaptanib sodium for macular edema secondary to central retinal vein occlusion,  Arch Ophth, April, 127(4):374-380, 2009

 

   

Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial.   Singerman LJ, Masonson H, Patel M, Adamis AP, Buggage R, Cunningham E, Goldbaum M, Katz B, Guyer D. , Br J Ophthalmol. 2008 Dec;92(12):1606-11. 2008.

 

Wrlblewski JJ, Welss JA, Adamis AP, Buggage RR, Cunningham ET, Goldbaum M, Guyer DR, Katz B, Altaweel MM,  Pegaptanib sodium for macular edema secondary to central retinal vein occlusion,  Arch Ophth, April, 127(4):374-380, 2009

 

 

More Information About Dr. Barrett Katz

Albert Einstein College of Medicine

Montefiore Medical Center

Material in this section is provided by individual faculty members who are solely responsible for its accuracy and content.

Contact

Montefiore Medical Center
111 East 210th Street
Bronx, NY 10467

Tel: 718.920.6662
bkatz@montefiore.org

 
Pubmed Search
Collexis Research Profiles
Einstein Research Profiles (ERP) is one of the innovative technologies to create collaborative bridges within and across the entire bench-to-bedside-to-population spectrum of research. The ERP website has been developed in partnership with Collexis to give investigators easy access to PubMed publications, coauthor networks, information about NIH grants, and research networks.